{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T13:42:44Z","timestamp":1780580564210,"version":"3.54.1"},"reference-count":18,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,1]]},"DOI":"10.1097\/nmd.0000000000000065","type":"journal-article","created":{"date-parts":[[2013,12,27]],"date-time":"2013-12-27T08:13:13Z","timestamp":1388131993000},"page":"18-24","source":"Crossref","is-referenced-by-count":9,"title":["Noninferiority of Perphenazine vs. Three Second-Generation Antipsychotics in Chronic Schizophrenia"],"prefix":"10.1097","volume":"202","author":[{"given":"Robert","family":"Rosenheck","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiqun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-5-20210208","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1198\/sbr.2011.10013","article-title":"Time to all-cause treatment discontinuation as the primary outcome in the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Schizophrenia Study.","volume":"3","author":"Davis","year":"2011","journal-title":"Stat Biopharm Res"},{"key":"R3-5-20210208","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1176\/ajp.2006.163.12.2029","article-title":"The costs of drugs for schizophrenia.","volume":"163","author":"Freedman","year":"2006","journal-title":"Am J Psychiatry"},{"key":"R4-5-20210208","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1002\/pst.507","article-title":"Determining the non-inferiority margin for patient reported outcomes.","volume":"10","author":"Gerlineger","year":"2011","journal-title":"Pharm Stat"},{"key":"R5-5-20210208","doi-asserted-by":"crossref","first-page":"526","DOI":"10.4088\/JCP.11m07162","article-title":"Minimum clinically important difference in the Positive and Negative Syndrome Scale using data from the CATIE schizophrenia trial.","volume":"73","author":"Hermes","year":"2012","journal-title":"J Clin Psychiatry"},{"key":"R6-5-20210208","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","article-title":"Measurement of health status. Ascertaining the minimal clinically important difference.","volume":"10","author":"Jaeschke","year":"1989","journal-title":"Control Clin Trials"},{"key":"R7-5-20210208","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1001\/archpsyc.63.10.1079","article-title":"Randomized controlled trial of effect on quality of life of second-generation versus first-generation antipsychotic drugs in schizophreniaCUtLASS 1.","volume":"63","author":"Jones","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"R8-5-20210208","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1093\/schbul\/13.2.261","article-title":"The Positive and Negative Syndrome Scale (PANSS) for schizophrenia.","volume":"13","author":"Kay","year":"1987","journal-title":"Schizophr Bull"},{"key":"R9-5-20210208","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1176\/appi.ajp.2009.08121809","article-title":"Clinical trials design lessons from the CATIE Study.","volume":"166","author":"Kraemer","year":"2009","journal-title":"Am J Psychiatry"},{"key":"R10-5-20210208","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.4088\/JCP.10com06607whi","article-title":"Another point of view: Superiority, noninferiority, and the role of active comparators.","volume":"72","author":"Kraemer","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"R11-5-20210208","doi-asserted-by":"crossref","first-page":"331","DOI":"10.4088\/JCP.10r06669","article-title":"Comparative effectiveness clinical trials in psychiatry: Superiority, non-inferiority and the role of active comparators.","volume":"72","author":"Leon","year":"2011","journal-title":"J Clin Psychiatry"},{"key":"R12-5-20210208","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)61764-X","article-title":"Second-generation versus first-generation antipsychotic drugs for schizophrenia: A meta-analysis.","volume":"373","author":"Leucht","year":"2009","journal-title":"Lancet"},{"key":"R14-5-20210208","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.schres.2011.09.018","article-title":"Extent of attaining and maintaining symptom remission by antipsychotic medication in the treatment of chronic schizophrenia: Evidence from the CATIE study.","volume":"133","author":"Levine","year":"2011","journal-title":"Schizophr Res"},{"key":"R15-5-20210208","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.schres.2007.09.006","article-title":"Extrapolation between measures of symptom severity and change: An examination of the PANSS and CGI.","volume":"98","author":"Levine","year":"2008","journal-title":"Schizophr Res"},{"key":"R17-5-20210208","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1176\/ajp.151.6.825","article-title":"Risperidone in the treatment of schizophrenia.","volume":"151","author":"Marder","year":"1994","journal-title":"Am J Psychiatry"},{"key":"R21-5-20210208","first-page":"2013","article-title":"Developing a policy for second- generation antipsychotic drugs. Health Affairs. 28:w782-w793. Published online July 21, 2009. Retrieved from .","volume":"26","author":"Rosenheck","year":"2009","journal-title":"Accessed on November"},{"key":"R22-5-20210208","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1097\/JCP.0b013e3181faf39b","article-title":"Does clinical judgment of baseline severity and changes in psychopathology depend on the patient population Results of a CGI and PANSS linking analysis in a naturalistic study.","volume":"30","author":"Schennach-Wolff","year":"2010","journal-title":"J Clin Psychopharmacol"},{"key":"R25-5-20210208","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1176\/ajp.154.4.457","article-title":"Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: Results of an international collaborative trial.","volume":"154","author":"Tollefson","year":"1997","journal-title":"Am J Psychiatry"},{"key":"R26-5-20210208","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/S0140-6736(08)61765-1","article-title":"The spurious advance of antipsychotic drug therapy.","volume":"373","author":"Tyrer","year":"2009","journal-title":"Lancet"}],"container-title":["Journal of Nervous & Mental Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/NMD.0000000000000065","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T04:14:30Z","timestamp":1620965670000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00005053-201401000-00005"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/nmd.0000000000000065","relation":{},"ISSN":["0022-3018"],"issn-type":[{"value":"0022-3018","type":"print"}],"subject":[],"published":{"date-parts":[[2014,1]]}}}